Diplomat Pharmacy — Q4 2015 Earnings Presentation
8 slides from Diplomat Pharmacy's earnings presentation, Feb 29, 2016
Slide 1: 4Q'15 & 2015 Financial Highlights
4Q’15 & 2015 Financial Highlights 1 4Q’14 4Q’15 % Change 2014 2015 % Change Revenue $612m $987m +61% $2.2b $3.4b +52% Total prescriptions dispensed 208,000 238,000 +14% 797,000 911,000 +14% Gross margins 6.7% 7.8% 110 bps 6.3% 7.8% 150 bps Adjusted EBITDA $10.5m $28.1m +168% $35.2m $95.0m +170% Adju
Slide 2: Fourth Quarter Results
2 Fourth Quarter Results (1) Based on dispensed prescriptions only. (2) Gross profit / net sales (i.e., based on dispensed and serviced prescriptions). Revenue 61% growth EBITDA margin 1.7% Adjusted EBITDA 168% growth Gross Profit /Prescription 67% growth ($ in millions) ($ in millions) 2.8% 7.8% 6.
Slide 3: Revenue by Therapeutic Class
3 Revenue by Therapeutic Class ($ in millions) 2015 % of Total 2014 2013 Oncology 1,432,091 $ 43% 1,068,751 $ 736,987 $ Hepatitis 520,771 15% <10% <10% Immunology 510,708 15% 438,145 378,685 Infusion 374,884 11% <10% <10% Multiple Sclerosis <10% N/A 226,805 169,470 Other (none greater than 10% in th
Slide 4: Components of Quarterly Revenue Growth
4 Components of Quarterly Revenue Growth ($ in millions) Quarterly Revenue Price inflation has comprised only 5-8% of revenue over the last 5 quarters Political pressure on price inflation, if successful, will have limited impact on Diplomat Value added services to pharma manufacturers are an opport
Slide 5: Annual Revenue by Drug Year Launch
5 Annual Revenue by Drug Year Launch $1.5B $2.2B $3.3B 5% 21% 2% 18% 3% 16% 95% $1.4B 77% $1.7B 63% $2.1B Drugs across all launch years continue to grow substantially over time 2012 and prior drugs have grown ~50% from 2013 to 2015 2015 a record year for FDA approval of specialty drugs, yet 2015 lau
Slide 6: Balance Sheet / Cash Flow snapshot
6 Balance Sheet / Cash Flow snapshot ($ in millions) Includes $12mm in cash-based contingent consideration Includes $6mm in cash-based contingent consideration December 31, 2014 2015 Cash $18 $28 Total Debt $12 (1) $123 (2) Shareholders’ equity $169 $516 Net Debt/ProForma EBITDA -- ~.8x Cash Flow Fr
Slide 7: 2016 Guidance
2016 Guidance 7 2015 Results 2016 Guidance Implied Midpoint Growth Revenue $3,367m $4.3b - $4.6b +32% Adjusted EBITDA $95.0m $116m - $123m +26% Adjusted EPS $0.75 $0.84 - $0.89 +15% 2016 guidance does not assume any incremental acquisitions 2016 assumes 67,500,000 shares outstanding throughout the y
Slide 8: 2016 Guidance
2016 Guidance Implied 2015 Results 2016 Guidance Midpoint Growth Revenue $3,367m $4.3b - $4.6b +32% Adjusted . EBITDA $95.0m $116m - $123m +26% Adjusted EPS $0.75 $0.84 - $0.89 +15% * 2016 guidance does not assume any incremental acquisitions * 2016 assumes 67,500,000 shares outstanding throughout t